Cargando…

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Tuberous sclerosis complex (TSC) is a genetic multisystem disorder characterized by the development of hamartomas in several organs. Mutations in the TSC1 and TSC2 tumor suppressor genes determin overactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalitie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moavero, Romina, Coniglio, Antonella, Garaci, Francesco, Curatolo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848592/ https://www.ncbi.nlm.nih.gov/pubmed/24044547 http://dx.doi.org/10.1186/1824-7288-39-57

Ejemplares similares

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis
por: Moavero, Romina, et al.
Publicado: (2016)

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis
por: Ramamurthy, Aishwarya, et al.
Publicado: (2023)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

Autism and Epilepsy in Patients With Tuberous Sclerosis Complex
por: Specchio, Nicola, et al.
Publicado: (2020)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
por: Brakemeier, Susanne, et al.
Publicado: (2017)

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
por: Polchi, Alice, et al.
Publicado: (2018)

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
por: Major, Philippe
Publicado: (2011)

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
por: Palavra, Filipe, et al.
Publicado: (2017)

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
por: Zhang, Bo, et al.
Publicado: (2013)

Event-Related Potentials in ADHD Associated With Tuberous Sclerosis Complex: A Possible Biomarker of Symptoms Severity?
por: Moavero, Romina, et al.
Publicado: (2020)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
por: Sugalska, Monika, et al.
Publicado: (2021)

mTOR inhibition rescues osteopenia in mice with systemic sclerosis
por: Chen, Chider, et al.
Publicado: (2015)

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2014)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis
por: Zimmer, Till S., et al.
Publicado: (2020)

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
por: Śmiałek, Dominika, et al.
Publicado: (2023)

mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile
por: Pawlik, Bartłomiej, et al.
Publicado: (2022)

Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent
por: Jaeschke, Anja, et al.
Publicado: (2002)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth
por: Dill, Patricia E, et al.
Publicado: (2015)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
por: Franz, David N., et al.
Publicado: (2017)

Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
por: McNamara, Molly C., et al.
Publicado: (2022)

The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
por: Mulder, Femke V. M., et al.
Publicado: (2022)

Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non–mTOR‐mediated etiologies
por: Cepeda, Carlos, et al.
Publicado: (2018)

Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility
por: Tomoto, Kyoichi, et al.
Publicado: (2021)

Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting
por: Kapur, Payal, et al.
Publicado: (2023)

Pml represses tumour progression through inhibition of mTOR
por: Bernardi, Rosa, et al.
Publicado: (2011)

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma()
por: Cho, Jinhyun, et al.
Publicado: (2016)

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
por: Saffari, Afshin, et al.
Publicado: (2019)

Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
por: Moavero, Romina, et al.
Publicado: (2020)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Genetics and Molecular Biology of Tuberous Sclerosis Complex
por: Napolioni, Valerio, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ucsg7ffh0m3pgrb9oiqr7k0lkl